PHIO's Aroon Indicator triggered a bullish signal on January 23, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 89 similar instances where the Aroon Indicator showed a similar pattern. In of the 89 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Momentum Indicator moved below the 0 level on January 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on PHIO as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for PHIO turned negative on January 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
PHIO moved below its 50-day moving average on January 29, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PHIO crossed bearishly below the 50-day moving average on January 29, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.613) is normal, around the industry mean (12.604). P/E Ratio (0.012) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). PHIO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (252.111).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PHIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of RNAi-based medical technologies and therapies
Industry Biotechnology
A.I.dvisor indicates that over the last year, PHIO has been closely correlated with RIGL. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if PHIO jumps, then RIGL could also see price increases.
Ticker / NAME | Correlation To PHIO | 1D Price Change % | ||
---|---|---|---|---|
PHIO | 100% | -6.08% | ||
RIGL - PHIO | 84% Closely correlated | -3.85% | ||
CLNN - PHIO | 83% Closely correlated | +1.87% | ||
HOOK - PHIO | 81% Closely correlated | -0.53% | ||
DARE - PHIO | 81% Closely correlated | N/A | ||
AZTR - PHIO | 74% Closely correlated | +1.99% | ||
More |